Literature DB >> 20079640

Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy.

Stephanie L Hines1, Jeff A Sloan, Pamela J Atherton, Edith A Perez, Shaker R Dakhil, David B Johnson, Pavan S Reddy, Robert J Dalton, Bassam I Mattar, Charles L Loprinzi.   

Abstract

BACKGROUND: Postmenopausal women with osteoporosis/osteopenia are at increased risk of fracture. Aromatase inhibitors further increase bone loss in these patients. This study evaluates whether zoledronic acid prevents the bone loss expected when these patients initiate letrozole. PATIENTS AND METHODS: Postmenopausal women with estrogen and/or progesterone receptor-positive breast cancer and a bone mineral density (BMD) T-score <-2.0 were given letrozole 2.5mg/vitamin D 400 international units daily, calcium 500mg twice daily, and 4mg zoledronic acid every 6 months. The BMD was assessed at baseline and 1 year. The primary endpoint was the mean change in lumbar spine (LS) BMD at 1 year.
RESULTS: Forty-six patients completed 1 year of treatment. LS BMD increased by 2.66% (p=0.01), femoral neck (FN) by 4.81% (p=0.01), and any measured endpoint by 4.55% (p=0.0052).
CONCLUSIONS: Zoledronic acid prevents bone loss in postmenopausal women with osteoporosis/osteopenia starting letrozole and is associated with improvements in BMD. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20079640      PMCID: PMC2854212          DOI: 10.1016/j.breast.2009.12.001

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  24 in total

Review 1.  Risedronate: a clinical review.

Authors:  C Crandall
Journal:  Arch Intern Med       Date:  2001-02-12

2.  Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.

Authors:  Garnet L Anderson; Marian Limacher; Annlouise R Assaf; Tamsen Bassford; Shirley A A Beresford; Henry Black; Denise Bonds; Robert Brunner; Robert Brzyski; Bette Caan; Rowan Chlebowski; David Curb; Margery Gass; Jennifer Hays; Gerardo Heiss; Susan Hendrix; Barbara V Howard; Judith Hsia; Allan Hubbell; Rebecca Jackson; Karen C Johnson; Howard Judd; Jane Morley Kotchen; Lewis Kuller; Andrea Z LaCroix; Dorothy Lane; Robert D Langer; Norman Lasser; Cora E Lewis; JoAnn Manson; Karen Margolis; Judith Ockene; Mary Jo O'Sullivan; Lawrence Phillips; Ross L Prentice; Cheryl Ritenbaugh; John Robbins; Jacques E Rossouw; Gloria Sarto; Marcia L Stefanick; Linda Van Horn; Jean Wactawski-Wende; Robert Wallace; Sylvia Wassertheil-Smoller
Journal:  JAMA       Date:  2004-04-14       Impact factor: 56.272

3.  Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC.

Authors:  Stephanie L Hines; Betty Mincey; Todor Dentchev; Jeff A Sloan; Edith A Perez; David B Johnson; Paul L Schaefer; Steve Alberts; Heshan Liu; Stephen Kahanic; Miroslaw A Mazurczak; Daniel A Nikcevich; Charles L Loprinzi
Journal:  Breast Cancer Res Treat       Date:  2009-02-12       Impact factor: 4.872

4.  Prevention of postmenopausal osteoporosis. A comparative study of exercise, calcium supplementation, and hormone-replacement therapy.

Authors:  R L Prince; M Smith; I M Dick; R I Price; P G Webb; N K Henderson; M M Harris
Journal:  N Engl J Med       Date:  1991-10-24       Impact factor: 91.245

5.  Does calcium supplementation prevent postmenopausal bone loss? A double-blind, controlled clinical study.

Authors:  B Riis; K Thomsen; C Christiansen
Journal:  N Engl J Med       Date:  1987-01-22       Impact factor: 91.245

6.  Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.

Authors:  M Baum; A U Budzar; J Cuzick; J Forbes; J H Houghton; J G M Klijn; T Sahmoud
Journal:  Lancet       Date:  2002-06-22       Impact factor: 79.321

7.  A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.

Authors:  R Charles Coombes; Emma Hall; Lorna J Gibson; Robert Paridaens; Jacek Jassem; Thierry Delozier; Stephen E Jones; Isabel Alvarez; Gianfilippo Bertelli; Olaf Ortmann; Alan S Coates; Emilio Bajetta; David Dodwell; Robert E Coleman; Lesley J Fallowfield; Elizabeth Mickiewicz; Jorn Andersen; Per E Lønning; Giorgio Cocconi; Alan Stewart; Nick Stuart; Claire F Snowdon; Marina Carpentieri; Giorgio Massimini; Judith M Bliss; Cornelius van de Velde
Journal:  N Engl J Med       Date:  2004-03-11       Impact factor: 91.245

8.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Authors:  Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272

9.  Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis.

Authors:  J T Harrington; L-G Ste-Marie; M L Brandi; R Civitelli; P Fardellone; A Grauer; I Barton; S Boonen
Journal:  Calcif Tissue Int       Date:  2003-12-05       Impact factor: 4.333

10.  Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk.

Authors:  Nelson B Watts; Cyrus Cooper; Robert Lindsay; Richard Eastell; Michael D Manhart; Ian P Barton; Tjeerd-Pieter van Staa; Jonathan D Adachi
Journal:  J Clin Densitom       Date:  2004       Impact factor: 2.963

View more
  17 in total

1.  2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary.

Authors:  Alexandra Papaioannou; Suzanne Morin; Angela M Cheung; Stephanie Atkinson; Jacques P Brown; Sidney Feldman; David A Hanley; Anthony Hodsman; Sophie A Jamal; Stephanie M Kaiser; Brent Kvern; Kerry Siminoski; William D Leslie
Journal:  CMAJ       Date:  2010-10-12       Impact factor: 8.262

Review 2.  Role of myeloid-derived suppressor cells in metastasis.

Authors:  Kathryn Cole; Kristina Pravoverov; James E Talmadge
Journal:  Cancer Metastasis Rev       Date:  2021-01-07       Impact factor: 9.264

3.  Construction of a database for the evaluation and the clinical management of patients with breast cancer treated with antiestrogens and/or aromatase inhibitors.

Authors:  Francesca Giusti; Silva Ottanelli; Laura Masi; Antonietta Amedei; Maria Luisa Brandi; Alberto Falchetti
Journal:  Clin Cases Miner Bone Metab       Date:  2011-01

Review 4.  Update on the use of zoledronic acid in the management of osteoporosis.

Authors:  David M Reid
Journal:  Curr Osteoporos Rep       Date:  2010-09       Impact factor: 5.096

Review 5.  Antiresorptive therapy in the management of cancer treatment-induced bone loss.

Authors:  Ashwani Garg; Kim Leitzel; Suhail Ali; Allan Lipton
Journal:  Curr Osteoporos Rep       Date:  2015-04       Impact factor: 5.096

6.  Bone marrow endothelium-targeted therapeutics for metastatic breast cancer.

Authors:  Junhua Mai; Yi Huang; Chaofeng Mu; Guodong Zhang; Rong Xu; Xiaojing Guo; Xiaojun Xia; David E Volk; Ganesh L Lokesh; Varatharasa Thiviyanathan; David G Gorenstein; Xuewu Liu; Mauro Ferrari; Haifa Shen
Journal:  J Control Release       Date:  2014-05-10       Impact factor: 9.776

Review 7.  Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass.

Authors:  Ronald C Hamdy
Journal:  Drug Des Devel Ther       Date:  2010-11-18       Impact factor: 4.162

Review 8.  Current and emerging treatment strategies for breast cancer-induced bone loss.

Authors:  Stephanie L Hines
Journal:  Breast Cancer (Dove Med Press)       Date:  2010-10-28

Review 9.  Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer.

Authors:  M Bauer; J Bryce; P Hadji
Journal:  Breast Cancer (Dove Med Press)       Date:  2012-06-20

10.  Cost-utility of adjuvant zoledronic acid in patients with breast cancer and low estrogen levels.

Authors:  N W D Lamond; C Skedgel; D Rayson; T Younis
Journal:  Curr Oncol       Date:  2015-08       Impact factor: 3.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.